iShares Genomics Imnlgy & Hlthcr ETF CAD (XDNA.TO)
30.91
-0.38
(-1.21%)
CAD |
TSX |
Apr 25, 16:00
Price Chart
Key Stats
| Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.44% | 0.05% | 4.634M | 133.93 |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
| 0.40% | 58.20% | 0.00 | Upgrade |
Basic Info
| Investment Strategy | |
| XDNA seeks to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an Index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determinedby the Index Provider. XDNA currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. Under normal market conditions, XDNA will primarily invest in securities of one or more iShares ETFs and/or international equity securities. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | BlackRock Asset Management Canada Ltd |
| Prospectus Benchmark Index | |
| NYSE FactSet Glb Gnmcs&Imm Bio NR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Not Disclosed | 1.93 yrs |
Performance Versus Category
As of April 25, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 25, 2024.
Basic Info
| Investment Strategy | |
| XDNA seeks to provide long-term capital growth by replicating, to the extent possible, the performance, net of expenses, of an Index selected at the discretion of BlackRock Canada that is composed of securities of issuers that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determinedby the Index Provider. XDNA currently seeks to replicate the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. Under normal market conditions, XDNA will primarily invest in securities of one or more iShares ETFs and/or international equity securities. |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Mid Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | BlackRock Asset Management Canada Ltd |
| Prospectus Benchmark Index | |
| NYSE FactSet Glb Gnmcs&Imm Bio NR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Not Disclosed | 1.93 yrs |